Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
FLXN Flexion Therapeutics, Inc. daily Stock Chart
FLXN [NASD]
Flexion Therapeutics, Inc.
Healthcare | Drugs - Generic | USA
financial highlights | statements
Index- P/E- EPS (ttm)-4.28 Insider Own1.30% Shs Outstand38.01M Perf Week-1.88%
Market Cap417.73M Forward P/E- EPS next Y-2.45 Insider Trans5.25% Shs Float36.48M Perf Month0.64%
Income-162.20M PEG- EPS next Q-0.97 Inst Own- Short Float23.58% Perf Quarter-12.22%
Sales44.10M P/S9.47 EPS this Y-8.00% Inst Trans-0.73% Short Ratio14.88 Perf Half Y-25.03%
Book/sh1.09 P/B10.08 EPS next Y37.60% ROA-57.70% Target Price24.89 Perf Year-48.52%
Cash/sh4.51 P/C2.44 EPS next 5Y- ROE-175.30% 52W Range8.76 - 23.10 Perf YTD-2.92%
Dividend- P/FCF- EPS past 5Y-29.50% ROI-59.30% 52W High-52.42% Beta1.31
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin84.40% 52W Low25.46% ATR0.69
Employees272 Current Ratio7.80 Sales Q/Q347.40% Oper. Margin- RSI (14)53.25 Volatility6.23% 6.72%
OptionableYes Debt/Eq3.81 EPS Q/Q17.50% Profit Margin- Rel Volume0.79 Prev Close10.73
ShortableYes LT Debt/Eq3.81 EarningsAug 06 AMC Payout- Avg Volume578.04K Price10.99
Recom1.80 SMA207.35% SMA500.91% SMA200-12.80% Volume459,098 Change2.42%
May-09-19Upgrade The Benchmark Company Hold → Buy $19
Jan-04-19Reiterated Needham Buy $42 → $36
Jan-04-19Downgrade The Benchmark Company Buy → Hold
Jun-28-18Initiated The Benchmark Company Buy $39
Oct-09-17Reiterated Needham Buy $36 → $42
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
May-14-15Initiated Northland Capital Outperform $40
Mar-31-15Initiated MLV & Co Buy $38
Aug-14-14Initiated Summer Street Research Buy $25
Mar-10-14Initiated Needham Buy $26
Aug-10-19 12:01PM  3 Healthcare Stocks With Rising Expectations Motley Fool
Aug-07-19 05:45PM  Edited Transcript of FLXN earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents +11.71%
04:26PM  Flexion Therapeutics, Inc. (FLXN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 06:35PM  Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Flexion Therapeutics Reports Second-Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
Aug-05-19 08:53AM  How Should Investors Feel About Flexion Therapeutics, Inc.'s (NASDAQ:FLXN) CEO Pay? Simply Wall St.
Aug-02-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -7.16%
Jul-30-19 04:30PM  Flexion Therapeutics to Report Second-Quarter 2019 Financial Results on August 6, 2019 GlobeNewswire
10:38AM  Will Flexion Therapeutics (FLXN) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-15-19 07:30AM  Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Patients with Advanced Knee OA GlobeNewswire +6.12%
Jul-05-19 06:47AM  Flexion Therapeutics, Inc. (NASDAQ:FLXN): When Will It Breakeven? Simply Wall St.
Jul-03-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-24-19 01:28PM  Heres What Hedge Funds Think About Flexion Therapeutics Inc (FLXN) Insider Monkey -6.44%
Jun-20-19 09:00AM  Flexion Therapeutics Named one of Boston Business Journals Best Places to Work for the Third Consecutive Year GlobeNewswire
Jun-18-19 04:30PM  Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-07-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-06-19 02:27PM  Edited Transcript of FLXN earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-05-19 08:30AM  Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis GlobeNewswire
May-30-19 06:58AM  If You Had Bought Flexion Therapeutics (NASDAQ:FLXN) Stock A Year Ago, You'd Be Sitting On A 56% Loss, Today Simply Wall St.
May-20-19 12:48PM  These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month Motley Fool
May-14-19 04:30PM  Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-12-19 09:50PM  Heres What Hedge Funds Think About Flexion Therapeutics Inc (FLXN) Insider Monkey
May-10-19 01:06PM  Flexion Therapeutics, Inc. (FLXN) Q1 2019 Earnings Call Transcript Motley Fool +8.74%
07:30AM  Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
May-09-19 11:58AM  Here's Why Flexion Therapeutics Jumped as Much as 18.4% Today Motley Fool +19.32%
09:45AM  Chevron, Conduent, Flexion, and More: Stocks in the Spotlight Insider Monkey
May-08-19 06:35PM  Flexion Therapeutics (FLXN) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.47%
05:25PM  Flexion Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-03-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-02-19 09:00AM  Flexion Therapeutics Announces Upcoming Presentations at the 2019 Osteoarthritis Research Society International (OARSI) World Congress GlobeNewswire
May-01-19 04:30PM  Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-25-19 07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
Apr-24-19 04:30PM  Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Apr-23-19 12:53PM  Flexion Therapeutics, Inc. (NASDAQ:FLXN): Time For A Financial Health Check Simply Wall St.
Apr-05-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-03-19 04:30PM  Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference GlobeNewswire
Apr-02-19 07:30AM  Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal Drugs GlobeNewswire
Apr-01-19 09:00AM  Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Board GlobeNewswire
Mar-11-19 08:00AM  Mutual Fund Managers Are Bullish On Stock Market Forecast But Some Are Hedging Bets Investor's Business Daily
Mar-04-19 04:30PM  Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference GlobeNewswire -5.02%
07:00AM  Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors CNW Group
03:18AM  Edited Transcript of FLXN earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-19 04:45PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.73%
Feb-28-19 08:20PM  Flexion Therapeutics Inc (FLXN) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results GlobeNewswire
Feb-26-19 04:30PM  Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference GlobeNewswire
Feb-21-19 04:30PM  Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage GlobeNewswire
10:31AM  Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-20-19 04:30PM  Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019 GlobeNewswire
Feb-12-19 09:46AM  Opening Bell, February 12, 2019 CNBC Videos
Feb-11-19 04:05PM  Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy GlobeNewswire
11:41AM  Here's Why Flexion Therapeutics Rose 29.8% in January Motley Fool
Feb-08-19 09:00AM  Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12 GlobeNewswire
Feb-01-19 05:00PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.74%
Jan-30-19 07:20AM  Consolidated Research: 2019 Summary Expectations for Telephone and Data, EMCOR Group, Chart Industries, Alarm, Flexion Therapeutics, and Social Reality Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-22-19 04:30PM  Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer GlobeNewswire -5.14%
Jan-04-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.41%
07:59AM  The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO Benzinga
Jan-03-19 04:36PM  Flexion shares plummet after weak revenue guidance MarketWatch
04:01PM  Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019 GlobeNewswire
12:05PM  Raymond James: Flexion Therapeutics Estimates Are A Stretch Benzinga
10:26AM  Flexion Starts Phase III Enrollment on Zilretta for Hip OA Zacks
Jan-02-19 04:30PM  Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study GlobeNewswire +10.07%
Dec-20-18 04:00PM  Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019 GlobeNewswire
Dec-17-18 04:30PM  Flexion Therapeutics Submits Supplemental New Drug Application (sNDA) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Dec-11-18 11:01AM  Here's Why Flexion Therapeutics Jumped 20.5% in November Motley Fool
Dec-04-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-18 10:07AM  2 Small Biotech Stocks That Insiders Are Buying TheStreet.com
Nov-27-18 01:53PM  Flexion Therapeutics Inc (NASDAQ:FLXN): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
08:45AM  New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-16-18 09:22AM  Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe GlobeNewswire
Nov-08-18 09:37PM  Edited Transcript of FLXN earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents +19.06%
Nov-07-18 07:30PM  Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:34PM  Flexion Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports Third-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Nov-05-18 06:30AM  Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019 GlobeNewswire
Oct-31-18 07:30AM  Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018 GlobeNewswire -5.45%
Oct-22-18 07:30AM  Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting GlobeNewswire -9.08%
Oct-16-18 08:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within Iamgold, Mazor Robotics, Flexion Therapeutics, Hemisphere Media Group, Criteo S.A, and EP Energy New Research Emphasizes Economic Growth GlobeNewswire +6.23%
Oct-05-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-10-18 09:00AM  Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology GlobeNewswire
Sep-07-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-28-18 04:30PM  Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference GlobeNewswire +5.04%
Aug-20-18 05:23PM  Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium GlobeNewswire
Aug-17-18 08:00AM  Report: Developing Opportunities within Adesto Technologies, BLACKLINE INC, Altice, Flexion Therapeutics, EZCORP, and CorVel Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-10-18 06:19AM  Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass. American City Business Journals
Aug-07-18 06:35PM  Flexion Therapeutics (FLXN) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:30PM  Flexion Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-30-18 04:30PM  Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-25-18 07:35AM  Free Technical Research on Evolus and Three More Generic Drugs Equities ACCESSWIRE -5.97%
Jul-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-21-18 09:00AM  Flexion Therapeutics Named one of Boston Business Journals Best Places to Work for the Second Year in a Row GlobeNewswire
Jun-19-18 07:15AM  Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks ACCESSWIRE
Jun-13-18 09:00AM  Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) PR Newswire
Jun-01-18 05:13PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Willwerth ChristinaChief Strategy OfficerAug 13Option Exercise0.168,7501,40067,169Aug 14 04:06 PM
Clayman Michael D.President and CEOAug 08Buy10.852,31725,13672,249Aug 08 04:38 PM
COLELLA SAMUEL DDirectorAug 08Buy10.742,00021,48045,333Aug 09 04:05 PM
Arkowitz DavidChief Financial OfficerMay 31Buy11.052,50027,62789,424Jun 03 04:18 PM
MERRIFIELD C ANNDirectorMay 23Buy12.648,000101,12010,000May 24 09:15 AM
Arkowitz DavidChief Financial OfficerMay 13Buy11.994,00047,96086,924May 15 04:05 PM
Clayman Michael D.President and CEOMay 10Buy12.484,01250,06774,868May 13 09:15 AM
Arkowitz DavidChief Financial OfficerMay 08Sale10.062,24822,61582,924May 09 04:32 PM
Clayman Michael D.President and CEOMar 12Buy12.364,04650,00970,856Mar 13 04:11 PM
Levine Mark S.General CounselJan 03Sale12.367349,0729,060Jan 04 05:12 PM
Wentworth KerryChief Regulatory OfficerJan 03Sale12.366227,68811,207Jan 04 05:10 PM
KELLEY SCOTTChief Medical OfficerJan 03Sale12.366227,68815,271Jan 04 05:09 PM
Bodick NeilChief Scientific OfficerJan 03Sale12.367469,22164,782Jan 04 05:06 PM
Clayman Michael D.President and CEOJan 03Sale12.363,27840,51666,810Jan 04 05:03 PM
Clayman Michael D.President and CEONov 09Buy17.105,00085,47769,166Nov 13 09:17 AM
Arkowitz DavidChief Financial OfficerNov 09Buy16.564,00066,22248,250Nov 13 09:14 AM
open in yahoo | open in reuters | open in google